Basit öğe kaydını göster

dc.contributor.authorTopcul, MEHMET RIFKI
dc.contributor.authorCetin, Idil
dc.date.accessioned2021-03-05T16:47:07Z
dc.date.available2021-03-05T16:47:07Z
dc.date.issued2014
dc.identifier.citationTopcul M. R. , Cetin I., "Endpoint of Cancer Treatment: Targeted Therapies", ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, ss.4395-4403, 2014
dc.identifier.issn1513-7368
dc.identifier.otherav_c24ca33c-6aa1-4090-a727-8d9643467498
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/128945
dc.identifier.urihttps://doi.org/10.7314/apjcp.2014.15.11.4395
dc.description.abstractNowadays there are several limitations in cancer treatment. One of these is the use of conventional medicines which not only target cancer cells and thus also cause high toxicity precluding effective treatment. Recent elucidation of mechanisms that cause cancer has led to discovery of novel key molecules and pathways which have have become successful targets for the treatments that eliminate only cancer cells. These so-called targeted therapies offer new hope for millions of cancer patients, as briefly reveiwed here focusing on different types of agents, like PARP, CDK, tyrosine kinase, farnysyl transferase and proteasome inhibitors, monoclonal antibodies and antiangiogenic agents.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleEndpoint of Cancer Treatment: Targeted Therapies
dc.typeMakale
dc.relation.journalASIAN PACIFIC JOURNAL OF CANCER PREVENTION
dc.contributor.departmentİstanbul Üniversitesi , Fen Fakültesi , Biyoloji Bölümü
dc.identifier.volume15
dc.identifier.issue11
dc.identifier.startpage4395
dc.identifier.endpage4403
dc.contributor.firstauthorID59633


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster